BOSTON , March 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
PTI-428, PTI-801 and PTI-808 Testing Underway in Organoids from CF Patients, with Potential for Clinical Data in 2020 HIT CF Project Funded by the European Union's Horizon 2020 Research and Innovation Programme BOSTON , Feb. 27, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc.
BOSTON , Feb. 20, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
BOSTON , Feb. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
Proprietary Triplet Successfully Completes First Cohort and Proceeds with Higher Dose Testing, Study Remains Blinded Company to Report Full Results of All Planned Proprietary Combination Studies in the First Quarter of 2019 Add-on Combination Studies with PTI-801 and PTI-428 on top SYMDEKO® Remain
Agreement Covers Small Molecule Modulators of the Cellular Proteostasis Network BOSTON , Dec. 17, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic
BOSTON , Nov. 21, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
BOSTON , Oct. 23, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
BOSTON , Oct. 22, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
PTI-801 and PTI-808 Dose Response Observed Across All Cohorts and Statistical Significance Achieved on All Endpoints Mean Change from Placebo of up to +8% in ppFEV1 and -13mM in Sweat Chloride Observed at Third Dose Level; Fourth and Highest Dosing Cohort Ongoing Screening of First Triplet
